Live Feeds
● LIVE Updated 1h ago · 11 sources tracked

Moderna Stock Plummets 18% After Cancer-Vaccine Data Leak

Moderna shares dropped sharply following an unauthorized data leak concerning its experimental melanoma vaccine developed alongside Merck. The decline follows a massive stock rally driven by optimism over the personalized treatment. Investors awaited the full late-stage trial results for the combination of intismeran autogene and Merck's Keytruda ahead of the European Society for Medical Oncology Congress. While reports indicated the fuller trial data released later appeared positive relative to Wall Street expectations, the initial leak left the stock down between 18% and 25% due to varying market reactions.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (11)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ Moderna shares dropped 18% after leaked melanoma vaccine trial data.
  • ✓ Moderna released full data on its closely watched cancer vaccine developed with Merck.
  • ✓ Investors awaited full data from the late-stage trial of intismeran autogene plus Merck's Keytruda at the European Society for Medical Oncology Congress on October 24.
  • ✓ Moderna and Merck previously stated their mRNA cancer vaccine cut death and recurrence by 42%.
🛡️ Source Corroboration: 11 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Moderna released full trial data for its personalized cancer vaccine following an earlier leak that caused heavy stock volatility.

Live updates

  1. Moderna Stock Plummets After Cancer-Vaccine Data Leak

    Moderna shares dropped sharply following an unauthorized data leak concerning its experimental melanoma vaccine developed alongside Merck. The decline follows a massive stock rally driven by optimism over the personalized treatment. Investors awaited the full late-stage trial results for the combination of intismeran autogene and Merck's Keytruda ahead of the European Society for Medical Oncology Congress. While reports indicated the fuller trial data released later appeared positive relative to Wall Street expectations, the initial leak left the stock down between 18% and 25% due to varying market reactions.

    Why it matters

    The experimental mRNA vaccine aims to tackle melanoma by reducing the risk of disease recurrence or death. Clinical trials previously demonstrated that the bespoke treatment cut death and recurrence rates significantly. Market volatility intensified as unvetted details surfaced before the official presentation window.

    What is confirmed

    • Moderna shares dropped 18% after leaked melanoma vaccine trial data.
    • Moderna released full data on its closely watched cancer vaccine developed with Merck.
    • Investors awaited full data from the late-stage trial of intismeran autogene plus Merck's Keytruda at the European Society for Medical Oncology Congress on October 24.
    • Moderna and Merck previously stated their mRNA cancer vaccine cut death and recurrence by 42%.

    Still unconfirmed

    • Moderna shares plunged around 25% amid the reported cancer-vaccine data leak.

    What to watch next

    • Full presentations and official data releases from the European Society for Medical Oncology Congress.
    • Subsequent market responses and analyst evaluations regarding the efficacy of intismeran autogene combined with Keytruda.
    Sources used for this update (13)
    1. finance.yahoo.com — Yahoo Finance - Stock Market Live, Quotes, Business & Finance News
    2. www.forbes.com — Download The Forbes App
    3. contents.premium.naver.com — [잠옷입고 경제공부] 세계 무역지도를 바꿀 사건!
    4. WSJ — Moderna’s Shares Plummet After Cancer-Vaccine Data Shared on Social Media
    5. Ars Technica — Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
    6. The Guardian — ‘Bespoke’ mRNA vaccine significantly reduces risk of melanoma recurrence or death, clinical trial shows
    7. Barron's — Moderna Stock Plummets 18% After Cancer-Vaccine Data Leak
    8. BBC — First personalised cancer vaccine cuts risk of disease returning in major trial
    9. www.cnbc.com — Moderna stock falls after cancer vaccine data leak - CNBC
    10. finance.yahoo.com — Moderna Stock Plunges 25% After Possible Cancer Vaccine Data Leak
    11. digg.com — Moderna shares plunge around 25% amid reported cancer-vaccine data leak · Digg
    12. gulfnews.com — Moderna stock plunged 18% after cancer vaccine data leak
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community